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Background: The aim of the US dialysis Prospective Payment System bundle, launched in January 2011, was
reduction and more accurate prediction of costs of services, whilst maintaining or improving patient care. Dialysis
facilities could either adopt the bundle completely (100%) in the first year of launch, or phase-in (25%) over four
years. Differences in practice patterns and patient outcomes were hypothesized to occur in facilities that phased-in
25% compared to those that did not.
Methods: Data are from STEPPS, a study of 51 small dialysis organization facilities designed to describe trends in
dialytic treatment before and after bundle implementation. Baseline was defined as October-December 2010;
follow-up as January-December 2011. Facility- and patient-level data were collected at enrollment and regularly
thereafter. Cox proportional hazards and linear multi-level models were used to estimate the effect of opting-in
25% (vs. 100%) on practice patterns and clinical outcomes.
Results: 12 facilities (patient n = 346) opted-in 25% and 37 facilities (patient n = 1296) opted-in 100% to the dialysis
bundle. At baseline, patients at 25% facilities were primarily covered by Medicare, were more likely to be black, and
were receiving higher monthly epoetin alfa (EPO) doses. Throughout 2011, patients in 100% facilities received lower
monthly EPO doses, and had lower mean hemoglobin concentrations; hospitalization and mortality rates were
numerically lower in 25% facilities but not statistically different.
Conclusions: The economic pressure for dialysis providers to work within an expanded composite rate bundle
whilst maintaining patient care may be a driver of practice indicator outcomes. Additional investigations are
warranted to more precisely estimate clinical outcomes in patients attending facilities enrolling into the bundle
100% relative to the previous fee-for-service framework.
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Small dialysis organizationBackground
In the United States, over 400,000 individuals have end
stage renal disease (ESRD) requiring dialysis treatment
to sustain life [1]. Patients suffer from high co-morbidity
burden, are frequently hospitalized, and face a mortality
rate of 194 per 1000 patient-years [1]. Given their health
status, frequent treatment schedule, and the growth of
the population [1,2], costs of treating ESRD patients,* Correspondence: kmonda@amgen.com
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unless otherwise stated.estimated at $34.3 billion in 2011, have placed a substan-
tial budgetary burden on the Centers for Medicare &
Medicaid Services (CMS) [1].
In January 2011 the updated prospective payment sys-
tem (PPS) for ESRD (i.e. the “expanded dialysis compos-
ite rate bundle”) was launched, with the objective of
reducing costs of services and more accurately predict-
ing expenditures while maintaining or improving patient
care [3]. Injectables such as epoetin alfa (EPO), darbe-
poetin alfa (DPO), iron, and activated vitamin D analogs
which had previously been reimbursed independently
were now included in the bundled payment. Dialysis. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(100%) into the dialysis bundle in 2011, or to phase-in
gradually (25% per year) over four years. Most facilities
(92.2%) enrolled 100%; large dialysis organizations (LDOs)
enrolled over 99% of their facilities immediately, but small
(SDOs) and independent dialysis organizations (IDOs),
and hospital-based facilities opted-in to a lesser extent [1].
This choice presented the opportunity to investigate the
effect of different economic drivers on practice patterns
and patient outcomes, as has been suggested [4-6], in fa-
cilities choosing to phase-into the dialysis bundle versus
those opting-in fully. Results might be particularly inform-
ative as CMS seeks to bundle payments for a number of
medical conditions.
Because LDOs have both a larger patient-base over
which to distribute costs and are able to negotiate volume
rebates, it was postulated that they may have an advantage
over the IDOs and SDOs in managing the financial impli-
cations of the PPS [6-8]. Shifts in practice patterns and
clinical indicators may be more evident in smaller organi-
zations, particularly in the first year of the transition.
We used data from the Study to Evaluate the Prospective
Payment System Impact on Small Dialysis Organizations
(STEPPS), a study designed to describe trends in dialytic
treatment before and after implementation of the expanded
bundle in a representative sample of SDO facilities.
Methods
Study design
STEPPS was a multi-center prospective observational
cohort study of patients receiving care in 51 dialysis fa-
cilities that were members of SDOs within the United
States. An SDO was defined as a dialysis provider that
was either a stand-alone facility or part of a chain with
50 or fewer facilities. Facility and patient selection for
STEPPS has been described previously [9]. Briefly, facil-
ities were selected from all free-standing US dialysis fa-
cilities circa 2006 that qualified as SDOs. Patients were
at least 18 years old, receiving dialysis, and had provided
informed consent. During the study, patients who dis-
continued were replaced with patients within the same
facility. The study received institutional review board ap-
proval from all participating facilities.
Data were collected between October 2010 and
September 2012. For this analysis, we used data between
October 2010 and December 2011. The baseline period
was defined as October 1, 2010 to December 31, 2010;
follow-up was from January 1, 2011 to December 31,
2011 (to capture the first year of the expanded PPS
when facilities phasing-in were enrolled 25%).
Data collection
The outcomes of interest for this study include ESA dos-
ing patterns (type/route), medication use, hemoglobinconcentrations and other laboratory parameters, hospitalization
events, and mortality. Patient- and facility-level data were
obtained using standardized electronic data collection
forms. Patient-level demographic, comorbidity, anthropo-
metric, laboratory, and medication data were collected
at enrollment and scheduled intervals thereafter. Data
on hospitalization events (dates and diagnoses), death,
and other censoring events were recorded by the facility
throughout follow-up. Although data on red blood cell
transfusion were collected, we know these data to be
under-reported [9], and that this under-reporting differs
by opt-in status (25% facilities were three times more
likely to report zero transfusions than 100% facilities).
Facility-level characteristics were collected at enrollment
and quarterly thereafter. Data validation included checks
for implausible values and verification of source documen-
tation (e.g. hospital records) from a sample of patients at
each facility.
Data considerations
Baseline characteristics are described for patients on study
between October and December 2010. Study participants
were required to be receiving in-center hemodialysis
(HD); those on peritoneal dialysis or home hemodialysis
were excluded due to small numbers. Dialysis modality
was assessed monthly. For patients switching modality,
only patient-time on HD was included. For the 3% of
patient-months with missing modality information, 17%
of this missing data were imputed based on information
available in the prior and subsequent months.
Erythropoiesis stimulating agent (ESA) use is reported
as the total monthly dose administered in the last eli-
gible month of each quarter. For this analysis, only epoe-
tin alfa values are reported as no darbepoetin alfa use
was recorded in the 25% facilities. Laboratory values are
reported as the last non-missing value from the last eli-
gible month in each quarter; values outside an a priori
specified acceptable range were set to missing. Medica-
tions such as iron, vitamin D, cinacalcet, and phosphate
binders are reported as any use (yes/no) within each
quarter. Dosing route was obtained for ESAs [intraven-
ous (IV) vs. subcutaneous (SC)] and for iron and vitamin
D (IV vs. oral); both are reported as last administered
route within the quarter.
Statistical analysis
For each patient, person-time accumulated from January
1, 2011 or date of eligibility to the end of follow-up de-
fined as the first of the following events: death, withdrawal
from study, facility transfer, or December 31, 2011. Event
rates were estimated as first events (mortality, mortality/
hospitalization composite) or total events (all hospitaliza-
tions) divided by the person-time at risk. For patients who
switched dialysis modality during follow-up, person-time
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under-assessment of events unrelated to modality switch.
Person-time was not extended past December 31, 2011.
Descriptive statistics are presented as counts and pro-
portions for categorical variables, and means and standard
deviations for continuous variables. We assessed imbal-
ance in baseline patient- and facility-level characteristics
between the 25% and 100% facilities in two ways: via
p-value associated with t-test, chi-square, or Wilcoxon, as
appropriate, and by calculating the standardized difference
which is comparable to the z-score of a standard normal
distribution and, unlike the p-value, is unaffected by sam-
ple size [10]; a difference of > |0.20| was considered mean-
ingful. Associations with time (quarterly trends) over 2011
as well as Q4 2010 to Q4 2011 comparisons were modeled
using generalized estimating equations with an unstruc-
tured covariance matrix accounting for clustering within
both facilities and patients over time.
The effect of receiving care at a 25% (vs. 100%) facility
was estimated using Cox proportional hazards regression
for mortality and a mortality/hospitalization composite out-
come (hereinafter referred to as “composite”); using nega-
tive binomial regression for hospitalization rate; and using
linear mixed effects regression for monthly hemoglobin
concentration and EPO dose. Results from three levels of
adjustment are presented: unadjusted, parsimonious, and
extended. Parsimonious models were built by including all
time-invariant variables with a baseline standardized differ-
ence of > |0.20| and then performing backwards selection
until only those that produced a change of >10% in the ef-
fect estimate when removed from the model remained [11].
We elected to not evaluate time-dependent variables that
showed imbalance across 25% and 100% facilities (limited
to vitamin D use, ferritin, transferrin saturation [TSAT],
and parathyroid hormone [PTH], see Table 1) as potential
confounders because i) many of these factors may be on
the causal pathway between the medical interventions and
the clinical outcomes of interest and, ii) there were a num-
ber of patients eligible during the follow-up period without
baseline data (253 replacement patients and nine from the
facility that enrolled in January 2011) who would have been
excluded from all models, thus impacting the precision of
our estimates. Extended models added in the patient-level
variables age, sex, race, and time on dialysis, and the
facility-level characteristic percent with Medicare as pri-
mary payer. Outcomes were also stratified by race. Baseline
values for covariates were used in all adjusted models. All
statistical models accounted for clustering within facilities
and within individuals over time, as appropriate. All ana-
lyses were conducted using SAS V9.2 (Cary, NC).
Results
STEPPS includes 51 dialysis facilities. At baseline, 12
facilities (patient n = 346) opted-in 25% and 37 facilities(patient n = 1296) opted-in 100% to the dialysis bundle.
Two facilities are not represented at baseline: one did not
include any eligible patients and the other enrolled in
January 2011. While facility-level characteristics at base-
line are mostly similar between 25% and 100% facilities,
25% facilities included a larger percentage of patients with
Medicare as primary payer. Patients receiving treatment at
25% facilities tended to be black, received dialysis longer,
and received higher monthly EPO doses (Table 1).
Between the beginning of Q4 2010 and the end of Q1
2011, STEPPS lost one 25% facility due to closure and
gained one 100% facility that enrolled in January 2011.
Quarterly patient-level characteristics are presented in
Table 2. In both 25% and 100% facilities, EPO doses
declined, the percentage of patients with hemoglobin
concentrations ≥12 g/dL declined while those with
hemoglobin <10 g/dL increased, the percentage of pa-
tients with ESAs dosed SC (vs. IV) increased, mean
ferritin levels increased, and phosphate binder use in-
creased. In all cases, changes were more pronounced in
100% versus 25% facilities. Additionally in 100% facilities,
cinacalcet use increased, and patients were more likely to
be treated with oral forms of vitamin D and iron.
Figure 1 presents the quarterly mean monthly EPO
dose and percentage of patients with hemoglobin con-
centrations <10 g/dL between baseline and Q4 2011.
By Q4 2011, 24% of patients at 100% facilities had
hemoglobin concentrations <10 g/dL (Q4 2010 vs. Q4
2011, p = 0.0001) compared to 13% of patients at 25%
facilities (p = 0.34). As compared to patients in 25% fa-
cilities, patients in 100% facilities were receiving lower
EPO doses at baseline and show a greater absolute and
relative decline in monthly dose (Q4 2010 vs. Q4 2011,
p < 0.0001 and p = 0.05 in 100% and 25% facilities,
respectively).
We assessed rates of mortality, hospitalization, and a
mortality/hospitalization composite in 25% and 100% fa-
cilities over 2011. Unadjusted annual rates for mortality
and hospitalization were higher in 100% facilities, com-
pared to 25% facilities [rate (95% CI) per 100 person-
years for mortality: 14.0 (11.9, 16.2) and 10.2 (6.7, 13.8);
hospitalization: 112.7 (106.6, 118.9) and 92.3 (81.6,
103.0); composite: 75.1 (69.4, 80.9) and 60.3 (50.5, 70.2),
respectively]. Causes of death were well-balanced across
facility type, with cardiovascular as primary (41.4% and
40.3% in 25% and 100% facilities, respectively) followed
by unknown cause (34.5% and 33.6% in 25% and 100%
facilities, respectively). Similarly, causes of hospitalization
were relatively well-balanced across facility type, although
cardiovascular-related reasons were nominally higher in
100% facilities (24.1% vs. 13.6%, results not shown). After
adjustment, patients receiving treatment in facilities
that opted-in 25% (vs. 100%) experienced numerically
fewer deaths [RR (95% CI) = 0.78 (0.54, 1.14)], fewer
Table 1 Baseline facility- and patient-level characteristics in the STEPPS study by dialysis facility 25% and 100% opt-in
status
BASELINE CHARACTERISTICS
N (%); mean ± SD
25% (n = 346, 12 facilities) 100% (n = 1296, 37 facilities) p-value |Standardized Difference|
Facility-level characteristics
South (vs.non-South) geographic region 5 (41.7) 17 (45.9) 0.80 0.09
Urban (vs.rural) 10 (83.3) 28 (75.7) 0.71 0.19
For profit status 12 (100.0) 30 (81.1) 0.17 0.68
Percent Medicare primary payer 78.1 ± 14.9 64.0 ± 17.6 0.02 0.86d
Patient-level characteristics
Age (years) 60.6 ± 15.6 61.6 ± 14.9 0.29 0.06
Male sex 201 (58.1) 738 (56.9) 0.70 0.02
Race
White 130 (37.6) 743 (57.3) 0.00 0.42d
Black 137 (39.6) 303 (23.4)
Other/Unknown 79 (22.8) 250 (19.3)
Primary Cause of CKD
Diabetes 151 (43.6) 604 (46.6) 0.05 0.15
Hypertension 110 (31.8) 328 (25.3)
Other/unknown 85 (24.6) 364 (28.1)
BMI (kg/m2) 28.6 ± 6.7 29.2 ± 7.7 0.16 0.08
Years on dialysis 4.1 ± 3.7 3.1 ± 3.1 <0.0001 0.29d
Medical History
Congestive Heart Failure 111 (32.1) 359 (27.7) 0.11 0.10
Hypertension 288 (83.2) 1121 (86.5) 0.12 0.09
Diabetes 148 (42.8) 623 (48.1) 0.08 0.11
Cancer (other than skin) 31 (9.0) 157 (12.1) 0.10 0.10
Vascular access typea
Arteriovenous fistula/graft 287 (82.9) 1013 (78.3) 0.06 0.12
Venous catheter 59 (17.1) 281 (21.7)
Laboratory valuesa
Hemoglobin (g/dL) 11.3 ± 1.3 11.2 ± 1.3 0.26 0.07
Hemoglobin group
<10 g/dL 41 (11.8) 194 (15.0) 0.15 0.12
10 – 12 g/dL 204 (59.0) 784 (60.5)
≥12 g/dL 99 (28.6) 317 (24.5)
PTH (pg/dL) 443.0 ± 344.3 358.4 ± 306.8 <0.0001 0.26e
Calcium (mg/dL) 8.9 ± 0.8 9.0 ± 0.7 0.02 0.14
Phosphorus (mg/dL) 5.3 ± 1.6 5.3 ± 1.6 0.68 0.03
TSAT (%) 28.7 ± 11.0 31.4 ± 12.3 <0.0001 0.23e
Ferritin (ng/mL) 642.6 ± 388.2 754.7 ± 466.8 <0.0001 0.26e
Albumin (g/dL) 3.8 ± 0.4 3.8 ± 0.4 0.44 0.05
ESA administrationa,b
EPO monthly dose (units) 62471 ± 61748 53655 ± 55605 0.02 0.15
IV (vs. SC) ESA route 299 (92.6) 1092 (92.0) 0.74 0.02
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IV only 239 (69.1) 891 (68.8) 0.69 0.08
Oral only 1 (0.3) 11 (0.8)
Both IV and Oral 5 (1.4) 17 (1.3)
No iron use 101 (29.2) 377 (29.1)
Vitamin D use
IV only 284 (82.1) 949 (73.2) <0.0001 0.32e
Oral only 0 (0.0) 37 (2.9)
Both IV and Oral 9 (2.6) 78 (6.0)
No Vitamin D use 53 (15.3) 232 (17.9)
Cinacalcet use 82 (23.7) 294 (22.7) 0.69 0.02
Phosphate binder use 232 (67.1) 791 (61.0) 0.04 0.13
aLast non-missing value in the baseline period; bAmong ESA users; cWithin the baseline period; dTime-invariant variable evaluated as potential confounder in
parsimonious modeling; eTime-variant variable not evaluated as potential confounder in parsimonious modeling.
BMI, body mass index; TSAT, transferrin saturation; PTH, parathyroid hormone; EPO, epoetin alfa; IV, intravenous; SC, subcutaneous.
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fewer composite events [RR (95% CI) = 0.80 (0.54, 1.19)],
received higher mean monthly EPO doses [54,610 (44,963,
64,256) vs. 42,156 (37,005, 47,307) units], achieved higher
mean hemoglobin concentrations [11.3 (11.1, 11.5) vs.
10.9 (10.8, 11.0) g/dL], had a smaller percentage of
patients with hemoglobin concentrations <10 g/dL [RR
(95% CI) = 0.54 (0.38, 0.75)] and a greater percentage of
patients with hemoglobin concentrations ≥12 g/dL [RR
(95% CI) = 1.85 (1.22, 2.83)] (Figure 2a-d).
Mean monthly EPO doses, hemoglobin levels, and the
percentage of patients with hemoglobin concentrations
<10 g/dL and ≥12 g/dL, stratified by race, are presented
in Additional file 1: Figure S1. We found the effect of
phasing into the PPS 25% (vs. 100%) on monthly EPO
dose was greater among black patients (Additional file 1:
Figure S1a). Differences in hemoglobin outcomes in 25%
opt-in (vs. 100%) facilities were observed for both white
and black patients, but not among patients reporting
other race (Additional file 1: Figure S1b-d). As a sensi-
tivity analysis we ran all models limited to the baseline-
eligible population in order to evaluate the effect of
excluding time-variant parameters with potential imbal-
ance across 25% and 100% facilities and found results to
be relatively unchanged, although statistically less precise
(results not shown).
Discussion
STEPPS was a prospective observational cohort study
designed to evaluate changes in clinical management
and outcomes in patients receiving dialysis within SDOs
over the PPS implementation period. We used a con-
temporaneous comparator group to explore the clinicalimplications of major changes in reimbursement among
two types of facilities: those opting for 100% reimburse-
ment of Medicare patients under the bundled payment
system (i.e. experimental group) vs. those electing to re-
ceive reimbursement under the bundled payment system
in 25% increments over four years (i.e. control group).
Leveraging this “natural experiment,” we evaluated the
effect of policy changes on dialysis practice patterns and
patient outcomes in a representative sample of SDOs
during the first year of the expanded composite rate dia-
lysis bundle (the year with the largest differences in fi-
nancial incentives).
The majority of STEPPS facilities opted fully into the dia-
lysis bundle, with 24% choosing to phase-in 25% over four
years. As was anticipated by clinicians, dialysis organiza-
tions, and policy analysts [12-15], we observed changes in
the use of injectable and oral medications and increases in
subcutaneous administration in all facilities consistent with
financial incentives; however, these changes were less pro-
nounced in 25% facilities. Similarly, we observed less pro-
nounced changes in laboratory values (hemoglobin levels,
serum ferritin and PTH) in 25% facilities. However, because
iron and vitamin D doses were not collected, analyses of
these data cannot address the comparative effectiveness of
IV vs. oral therapies.
While the majority of patient and facility characteris-
tics were relatively balanced among the 25% and 100%
facilities before bundle implementation, the few excep-
tions are revealing. Notably, 25% facilities were more
likely to have greater proportions of patients who were
black, who were receiving higher monthly EPO doses,
and had Medicare as their primary payer. Dialysis pro-
viders understand the cost drivers within their facilities;
Table 2 Trends by quarter within 2011 in medication use and laboratory values by dialysis facility 25% and 100% opt-in status
25% facilities (N = 11) 100% facilities (N = 38)


















EPO monthly dose (units) 67624 ± 64409 62226 ± 64937 59134 ± 64567 54814 ± 57216 <0.0001 46294 ± 48614 46071 ± 47388 37973 ± 41916 40892 ± 43618 <0.0001
IV EPO monthly dose (units) 68687 ± 64337 63694 ± 65008 58813 ± 64117 55029 ± 56670 <0.0001 45455 ± 47892 45503 ± 46503 37300 ± 41087 42225 ± 45218 <0.0001
SC EPO monthly dose (units) 54904 ± 65232 46254 ± 63186 62404 ± 70244 52500 ± 64087 0.89 53561 ± 54168 51289 ± 54835 43056 ± 47596 33294 ± 32131 0.59
SC (vs.IV) ESA routeb 25 (7.7) 26 (8.4) 26 (8.9) 24 (8.5) 0.22 112 (9.6) 105 (9.1) 122 (11.4) 152 (14.8) <0.0001
Other medicationsc
Cinacalcet use 97 (28.0) 92 (28.3) 85 (27.3) 81 (27.2) 0.43 336 (26.5) 370 (29.9) 359 (30.8) 356 (31.6) <0.0001
Phosphate binder use 237 (68.5) 226 (69.5) 229 (73.6) 214 (71.8) 0.85 849 (67.1) 883 (71.4) 872 (74.8) 827 (73.5) <0.0001
Iron use 251 (72.5) 221 (68.0) 216 (69.5) 223 (74.8) 0.9 903 (71.3) 917 (74.2) 817 (70.1) 752 (66.8) 0.004
Oral (vs.IV) iron routeb 1 (0.4) 1 (0.5) 2 (0.9) 3 (1.3) - 8 (0.9) 13 (1.4) 14 (1.7) 13 (1.7) 0.21
Vitamin D use 294 (85.0) 275 (84.6) 254 (81.7) 246 (82.6) 0.20 975 (77.0) 967 (78.2) 927 (79.5) 914 (81.2) 0.001
Oral (vs.IV) vitamin D routeb 11 (3.7) 6 (2.1) 3 (0.2) 4 (2.1) 0.03 151 (15.5) 202 (20.9) 219 (23.6) 226 (24.7) <0.0001
Laboratory valuesa
Hemoglobin (g/dL) 11.3 ± 1.2 11.3 ± 1.3 11.3 ± 1.3 11.0 ± 1.1 0.0002 11.1 ± 1.3 11.0 ± 1.2 10.9 ± 1.3 10.7 ± 1.2 <0.0001
Hemoglobin <10 g/dL 41 (11.8) 37 (11.4) 41 (13.2) 40 (13.4) 0.34 229 (18.1) 226 (18.3) 251 (21.5) 268 (23.8) <0.0001
Hemoglobin ≥12 g/dL 96 (27.7) 92 (28.3) 87 (28.0) 52 (17.4) 0.004 314 (24.8) 225 (18.2) 210 (18.0) 132 (11.7) <0.0001
PTH (pg/dL) 393.4 ± 332.9 500.8 ± 404.4 412.1 ± 330.7 458.7 ± 355.3 0.70 380.2 ± 305.9 399.2 ± 315.4 414.3 ± 321.8 436.3 ± 343.7 <0.0001
Calcium (mg/dL) 8.8 ± 0.8 8.8 ± 0.8 8.9 ± 0.7 8.9 ± 0.7 0.06 8.9 ± 0.6 8.9 ± 0.7 8.9 ± 0.7 8.8 ± 0.7 <0.0001
Phosphorus (mg/dL) 5.2 ± 1.5 5.4 ± 1.7 5.4 ± 1.6 5.2 ± 1.5 0.63 5.2 ± 1.6 5.3 ± 1.6 5.3 ± 1.7 5.2 ± 1.6 0.14
TSAT (%) 30.8 ± 12.9 30.9 ± 12.7 33.0 ± 13.8 30.1 ± 11.4 0.82 32.7 ± 12.5 32.9 ± 12.6 33.5 ± 12.3 31.6 ± 11.7 0.19
Ferritin (ng/mL) 677.7 ± 383.2 663.6 ± 409.8 739.6 ± 405.9 693.8 ± 364.0 0.001 826.8 ± 438.0 849.2 ± 456.3 933.5 ± 471.8 922.6 ± 472.8 <0.0001
aAssessed during last eligible month in each quarter; bLast administered route in each quarter among users; cAny use during the quarter.













Figure 1 Unadjusted quarterly mean (95% confidence interval) epoetin alfa dose (lines) and percentage of subjects with hemoglobin
concentrations <10 g/dL (bars) by 25% and 100% dialysis facility opt-in status. Hb, hemoglobin; EPO, epoetin alfa.
Figure 2 The effect of dialysis facility opt-in status on outcomes. A. Hospitalization, mortality, and their composite. B. Monthly EPO dose. C. Hb
concentration. D. Percentage of patients with Hb <10 and >=12 g/dL. *Unadjusted; **Adjusted for race (mortality), insurance (EPO dose, Hb
outcomes); ***Adjusted for insurance, race, age, sex, and time on dialysis. EPO, epoetin alfa; Hb, hemoglobin. Bars represent 95% confidence intervals.
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and pre-PPS ESA utilization could have easily played a
role during the opt-in decision-making process. After
statistical adjustment, we continued to observe higher
EPO doses and higher mean hemoglobin levels in 25%
facilities. However, upon evaluating hospitalizations,
mortality, and their composite, we observed effects in
the 25% facilities to be numerically lower and direction-
ally consistent, but statistically imprecise. Our findings
are consistent with those reported from the United
States Renal Data System (USRDS) [1], as well as the
DOPPS Practice Monitor (DPM) which was established
to evaluate the impact of the dialysis bundle on practice
patterns and clinical care [16].
Previously, we found changes in anemia management
to be more pronounced among black patients as com-
pared to other racial groups [9]. The DPM has also re-
ported more substantial hemoglobin declines among
black patients [17]. While we observe a differential mean
monthly EPO dose between those facilities opting-in
25% vs. 100%, adjusting for race attenuates this effect,
suggesting that race is confounding the association
between opt-in status and dose. While the interplay be-
tween race, dose, dose changes, and whether this inter-
play entered into a facility's decision-making process
is complex, the exclusion of race as a case-mix adjuster
in the calculation of per-treatment bundled payment
has continued to be a source of concern among the
renal community given that black patients require higher
ESA doses to achieve comparable hemoglobin concen-
trations [14,18-22].
Outside the US there are has been a limited number
of investigations assessing the effects of bundling pol-
icies on patient outcomes in the dialysis setting. In 2006,
Japan implemented a bundled payment policy to cover
outpatient hemodialysis therapy with the stated aim of
lowering dialysis payments by 4%. Comparing cross-
sections of patients in Japanese DOPPS facilities before
and after the implementation of the payment policy,
Hasegawa et al. report an 11.8% decrease in EPO doses
and a concomitant increase in the percentage of patients
prescribed IV iron, with no change in mean hemoglobin
levels (10.4 g/dL before and after the policy change)
[23]. Portugal transitioned in 2008 from a fee-for-service
to a capitated payment system for hemodialysis, imple-
mented in conjunction with clinical quality indicators
required for reimbursement. Ponce et al. evaluated
changes in clinical outcomes before and two years after
implementation of capitation and observed only minor
differences determined to be independent of case-mix
[24]. Notably, however, the authors suggested that the
bundled payment system incentivized “compliance ra-
ther than performance.” In an analysis of the DOPPS
data from Germany where dialysis procedure rates werechanged in 2002 from per-session to weekly flat rate
payments, Kleophas and colleagues report “overall no
negative developments” with the reimbursement changes
and concomitant implementation of a quality assurance
program [25]. In contrast to these investigations that
compared practice changes before and after implementation
of capitated payment systems, our analysis attempts to
compare practice and outcome changes in two contem-
porary cohorts; one under full transition to a bundled
payment system and the other experiencing a staged ap-
proach. Consistent with the economic incentives of cap-
itated payments, results suggest more pronounced
practice pattern changes in facilities that enrolled in the
fully capitated model, with a potentially deleterious ef-
fect on clinical outcomes.
Our study is limited in several ways. Sparse data are
available prior to PPS implementation during which we
evaluated differences in patient- and facility-level charac-
teristics (limited to Q4 2010). Dialysis providers may have
begun altering their practice patterns early in 2010, as
noted by the USRDS [26] and further evidenced by the
rise in home hemodialysis modalities observed [26], and
thus our baseline period may not be entirely reflective
of the pre-bundle period. However, if practice pattern
changes were early and occurring before our ability to
capture them, then we would expect our estimates of ef-
fect to be biased toward the null. Likewise, there were a
number of patients enrolled into STEPPS after the base-
line period who are not represented in baseline data. We
also excluded the time-variant parameters found to be im-
balanced across 25% and 100% facilities as potential con-
founders in our statistical models, which may bias our
estimates if these values affect both the opt-in decision
and the outcomes studied. However, similar effect esti-
mates from sensitivity analyses in which these variables
were included suggest that confounding was not a major
concern. Assessments of hospitalizations and mortality
are potentially underreported given that they are reported
by the facilities and are not derived from claims or death
notification forms. Further, although simple descriptive
analyses suggest that patients in 25% facilities are less
likely to receive a transfusion than those in 100% facilities
(results not shown) we were unable to assess differences
in transfusion rates given that data capture differed by fa-
cility opt-in status. Next, given the small number of facil-
ities that phased-in 25% and the one year of follow-up
time, we have limited power to detect an effect on clinical
outcomes; nonetheless, results are directionally consistent
despite their lack of precision and provide rationale for
further, larger, studies of this nature. Additionally, any
study that is of a non-randomized nature is subject to
biases that are less controllable. However, patient- and
facility-level characteristics were relatively well balanced
across facility types, and by comparing at a facility level
Monda et al. BMC Nephrology  (2015) 16:67 Page 9 of 10we gain an increased ability to control for unmeasured
factors. Finally, by design, this analysis is limited to the
first year of the expanded bundle implementation; future
research should assess whether the differential effect di-
minishes over time by including subsequent years when
phasing facilities are subject to increased capitation.
Conclusions
In summary, STEPPS is composed of a representative
sample of SDOs that provides valuable insights into the
effects of the ESRD PPS on practice patterns and patient
outcomes. CMS’s implementation of the ESRD expanded
composite rate dialysis bundle is an important policy
change with substantial implications, given the interest
in containing health care costs for other disease condi-
tions via introduction of future bundled payment pol-
icies. Leveraging the 25% vs. 100% analytic framework
allows us to evaluate policy changes on patient care in a
timeframe during which dialysis providers were subject
to similar pressures but with differential time horizons.
Herein, we observe pronounced effects on practice indi-
cators which are thought to be economically driven, and
which might have been anticipated, given the dialysis
providers’ need to maintain patient care within a capi-
tated payment structure without being at an economic
disadvantage as a result of continuing to treat dialysis
patients. Nonetheless, we note that the decision to
choose whether to opt in 100% or phase-in 25% over
four years was likely a complex one, given each center’s
unique situation regarding costs, economic acumen and
nimbleness (requiring a sophisticated understanding of
the QIP and resulting effects on future payment years),
patient and payer case-mix, and stated mission. Given that
these results are from a relatively small subset of the entire
population affected by the dialysis bundle, additional in-
vestigations are warranted to provide more precise esti-
mates of the clinical outcomes experienced by patients in
centers enrolling into the bundle 100% relative to the pre-
vious fee-for-service capitation framework.
Additional file
Additional file 1: Figure S1. The effect of dialysis facility opt-in status
on outcomes, by race. A. Monthly EPO dose. B. Hb concentration. C.
Likelihood of having Hb <10 g/dL. D. Likelihood of having Hb >=12 g/dL.
*Unadjusted; **Adjusted for insurance (EPO dose, Hb level, percentage of
subjects with Hb >=12 g/dL); ***Adjusted for insurance, age, sex, and
time on dialysis. EPO, epoetin alfa; Hb, hemoglobin. Bars represent 95%
confidence intervals.
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